Total Payments
$344.86
2024 Payments
$148.34
Companies
2
Transactions
20
Medicare Patients
2,793
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$344.86 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $344.86 | 20 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $326.15 | 19 | $0 (2024) |
| PFIZER INC. | $18.71 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $148.34 | 8 | Amgen Inc. ($148.34) |
| 2023 | $159.41 | 10 | Amgen Inc. ($159.41) |
| 2022 | $18.40 | 1 | Amgen Inc. ($18.40) |
| 2018 | $18.71 | 1 | PFIZER INC. ($18.71) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Inflammation | ||||||
| 06/06/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Inflammation | ||||||
| 04/17/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Inflammation | ||||||
| 04/03/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Inflammation | ||||||
| 03/13/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Inflammation | ||||||
| 02/14/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: Inflammation | ||||||
| 01/22/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Inflammation | ||||||
| 01/03/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Inflammation | ||||||
| 11/29/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Inflammation | ||||||
| 11/15/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: Inflammation | ||||||
| 09/12/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Inflammation | ||||||
| 05/11/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Inflammation | ||||||
| 05/03/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: Inflammation | ||||||
| 05/02/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $26.05 | General |
| Category: Inflammation | ||||||
| 03/06/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $7.87 | General |
| Category: Inflammation | ||||||
| 02/15/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Inflammation | ||||||
| 02/14/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $4.59 | General |
| Category: Inflammation | ||||||
| 01/25/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: Inflammation | ||||||
| 08/30/2022 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Inflammation | ||||||
| 01/10/2018 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 608 | 4,763 | $733,800 | $165,776 |
| 2022 | 8 | 676 | 4,211 | $694,800 | $190,787 |
| 2021 | 8 | 707 | 65,260 | $937,460 | $431,873 |
| 2020 | 9 | 802 | 71,876 | $1.1M | $492,585 |
Total Patients
2,793
Total Services
146,110
Medicare Billing
$1.3M
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | Office | 2023 | 11 | 2,690 | $269,000 | $63,662 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 221 | 403 | $100,750 | $32,320 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 221 | 395 | $79,000 | $22,462 | 28.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 12 | 840 | $84,000 | $20,598 | 24.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 31 | 220 | $132,000 | $18,370 | 13.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 88 | 101 | $25,250 | $5,498 | 21.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 82 | $24,600 | $1,545 | 6.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 32 | $19,200 | $1,322 | 6.9% |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | Office | 2022 | 13 | 2,870 | $287,000 | $94,508 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 187 | 327 | $81,750 | $26,402 | 32.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 159 | 293 | $73,250 | $24,867 | 33.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 32 | 249 | $149,400 | $22,103 | 14.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 173 | 286 | $57,200 | $16,416 | 28.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 81 | 87 | $17,400 | $2,756 | 15.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 18 | $4,500 | $2,171 | 48.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 14 | 81 | $24,300 | $1,564 | 6.4% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2021 | 11 | 62,360 | $374,160 | $274,771 | 73.4% |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | Office | 2021 | 13 | 1,550 | $155,000 | $60,563 | 39.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 266 | 452 | $113,000 | $36,053 | 31.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 35 | 259 | $155,400 | $25,551 | 16.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 243 | 413 | $82,600 | $22,579 | 27.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 77 | 80 | $16,000 | $5,534 | 34.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 47 | 50 | $12,500 | $4,774 | 38.2% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 15 | 96 | $28,800 | $2,049 | 7.1% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2020 | 12 | 67,520 | $405,120 | $280,616 | 69.3% |
About Dr. Jaime Vivas, M.D
Dr. Jaime Vivas, M.D is a Rheumatology healthcare provider based in Columbus, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700981503.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jaime Vivas, M.D has received a total of $344.86 in payments from pharmaceutical and medical device companies, with $148.34 received in 2024. These payments were reported across 20 transactions from 2 companies. The most common payment nature is "Food and Beverage" ($344.86).
As a Medicare-enrolled provider, Vivas has provided services to 2,793 Medicare beneficiaries, totaling 146,110 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Columbus, GA
- Active Since 09/14/2006
- Last Updated 08/24/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700981503
Products in Payments
- Enbrel (Biological) $326.15
- XELJANZ (Drug) $18.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Columbus
Dr. Kevin Schlessel, M.d, M.D
Rheumatology — Payments: $95,178
Rheumatology $95,178
Sheryl Mascarenhas, Md, MD
Rheumatology — Payments: $15,611
Rheumatology $15,611
Heather Lake, Do, DO
Rheumatology — Payments: $13,921
Rheumatology $13,921
Dr. Matthew Mundwiler, Md, MD
Rheumatology — Payments: $12,782
Rheumatology $12,782
Marc Antonchak, M.d, M.D
Rheumatology — Payments: $10,574
Rheumatology $10,574
Navya Parsa, Md, MD
Rheumatology — Payments: $8,302
Rheumatology $8,302